SCHEMBL16211565

SCHEMBL16211565

Nc1ncccc1Cc1ccccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
HRH1 P35367 2/20 0.47
ASIC3 Q9UHC3 1/20 0.44
PNP P00491 1/20 0.43
HRH3 Q9Y5N1 2/20 0.43
MAOA P21397 2/20 0.42
MAOB P27338 2/20 0.42
HRH4 Q9H3N8 1/20 0.42
LMNA P02545 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
ALDH1A1 P00352 1/20 0.42
ALOX15 P16050 1/20 0.42
BACE1 P56817 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LIN28A Q9H9Z2 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
KDM1A O60341 1/20 0.41
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28343693 0.83 L3MBTL1 (0.53) L3MBTL1HRH1HRH3MAOAMAOB
SCHEMBL7112576 0.82 L3MBTL1 (0.55) L3MBTL1HRH1ASIC3PNPHRH3
SCHEMBL9539943 0.81 L3MBTL1 (0.50) L3MBTL1HRH1ASIC3PNPHRH3
SCHEMBL6755614 0.79 L3MBTL1 (0.51) L3MBTL1HRH1ASIC3PNPHRH3
SCHEMBL7230325 0.78 HRH1 (0.53) L3MBTL1HRH1ASIC3PNPHRH3
SCHEMBL2259723 0.78 LTA4H (0.53) L3MBTL1MAOAMAOBBACE1SMN1; SMN2
SCHEMBL28551226 0.78 L3MBTL1 (0.50) L3MBTL1HRH1HRH3HRH4LMNA
SCHEMBL8392790 0.78 L3MBTL1 (0.50) L3MBTL1HRH1ASIC3PNPHRH3
SCHEMBL8668106 0.77 L3MBTL1 (0.44) L3MBTL1HRH1HRH3MAOAMAOB
SCHEMBL16211702 0.76 L3MBTL1 (0.45) L3MBTL1HRH1ASIC3PNPHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2991978-B1 BIHETEROARYL COMPOUNDS AND USES THEREOF F HOFFMANN LA ROCHE SA (CH) 2025-08-20 EP disclosed
US-11129832-B2 Biheteroaryl compounds and uses thereof GENENTECH, INC. (US) 2021-09-28 US disclosed
US-11129832-B2 Biheteroaryl compounds and uses thereof GENENTECH, INC. (US) 2021-09-28 US disclosed
US-20200188397-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2020-06-18 US disclosed
WO-2020120697-A1 PESTICIDALLY-ACTIVE CYANAMIDE HETEROCYCLIC COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2020-06-18 WO disclosed
US-20200188397-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2020-06-18 US disclosed
US-10010549-B2 Biheteroaryl compounds and uses thereof GENENTECH, INC. (US) 2018-07-03 US disclosed
US-10010549-B2 Biheteroaryl compounds and uses thereof GENENTECH, INC. (US) 2018-07-03 US disclosed
US-10010549-B2 Biheteroaryl compounds and uses thereof GENENTECH, INC. (US) 2018-07-03 US disclosed
US-20180133219-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-05-17 US disclosed
US-20180133219-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-05-17 US disclosed
US-20180133219-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-05-17 US disclosed
CN-105431420-A Diheteroaryl compounds and uses thereof HOFFMANN LA ROCHE 2016-03-23 CN disclosed
EP-2991978-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF F. Hoffmann-La Roche SA (CH) 2016-03-09 EP disclosed
US-20160052940-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-02-25 US disclosed
WO-2014177060-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF F.HOFFMANN-LA ROCHE AG (CH) 2014-11-06 WO disclosed
WO-2014177060-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF F.HOFFMANN-LA ROCHE AG (CH) 2014-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10010549-B2 Biheteroaryl compounds and uses thereof BCHE, SNCA, HAX1 L3MBTL1 1843/4885HRH1 560/4885ASIC3 1322/4885
US-11129832-B2 Biheteroaryl compounds and uses thereof BCHE, SNCA, HAX1 L3MBTL1 1843/4885HRH1 560/4885ASIC3 1322/4885
US-20180133219-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF BCHE, SNCA, HAX1 L3MBTL1 1843/4885HRH1 560/4885ASIC3 1322/4885
US-20160052940-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF BCHE, SNCA, HAX1 L3MBTL1 1843/4885HRH1 560/4885ASIC3 1322/4885
US-20200188397-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF BCHE, SNCA, HAX1 L3MBTL1 1843/4885HRH1 560/4885ASIC3 1322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.